洛铂联合吉西他滨治疗晚期肺癌安全性的临床观察  

The Clinical Observation of Safety of Lobaplatin and Gemicitabine Combination for Treating Advanced Lung Cancer

作　　者：任俊红[1] 黄新恩[2] 蔡炜宇[2] 江伟[2] 孙蔚莉[2] 夏国豪[2] 

机构地区：[1]无为县血防站,安徽无为238300 [2]江苏省肿瘤医院内科,江苏南京210009

出　　处：《肿瘤基础与临床》2007年第6期489-490,共2页journal of basic and clinical oncology

基　　金：江苏省人事厅"六大人材高峰"项目

摘　　要：目的观察评价新一代铂类抗癌药物洛铂(labaplatin,LBP)联合吉西他滨(gemicitabine,GEM)组成的GP方案治疗晚期肺腺癌和晚期小细胞肺癌(SCLC)的安全性。方法开放性、单试验组、Ⅰ期临床研究,共入组2例,均为常规放化疗效果差的患者,男性1例,女性1例,年龄分别为79岁、53岁。病理类型分别为小细胞肺癌(广泛期)、肺腺癌(Ⅳ期)。应用GP方案,即LBP 30 mg/m2,静滴,d1;GEM1 000 mg/m2,静滴,d1,8,21 d为1个周期。其中男性SCLC患者接受1个周期化疗、女性NSCLC患者接受1.5个周期化疗,按照WHO和NCI标准评价客观疗效和毒副反应,定期随访。结果2例毒副反应主要表现为可逆性的骨髓抑制、胃肠道反应、一过性肝损害、脱发,未见明显心肾毒性。结论LBP联合GEM组成GP方案治疗晚期NSCLC和SCLC的毒副反应可以耐受,可进一步研究观察。Objective To observe the safety profile of lobaplatin and gemicitabine combination in the treatment of advanced lung cancer. Methods Two patients were pathologically diagnosed with small cell lung cancer and adenocarcinoma of lung who relapsed after previous chemotherapy, they were treated by lobaplatin 30 mg/m^2 intravenously infusion （iv） on day 1, gemicitabine 1 000 mg/m^2 iv day 1 and day 8, repeated every 21 days. Toxicity and response were determined by NCl and WHO criteria respectively. Results The male patient with small cell lung cancer received one cycle, another female patient with adenocarcinoma got one and half cycle treatment. The main toxicity was reversible myelosuppression; other side effects included gastrointestinal toxicity, liver impairment, alopecia. Cardiac and renal toxicity was not detected. Conclusions Lobaplatin and gemicitabine combination was well tolerated in these two patients with lung cancer. The effectiveness of lobaplatin and gemicitabine combination in the treatment of lung cancer, especially none small cell lung cancer could be further examined.

关 键 词：洛铂 吉西他滨 晚期非小细胞肺癌和晚期小细胞肺癌 安全性 耐受 毒副反应 化疗 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]